Frequently Asked Questions

Brainomix 360 Stroke includes the following modules, each independently licensed or available as a package:
‍
• NCCT (e-ASPECTS) — automated ASPECTS scoring, LVO detection, ischemic core volume, and Net Water Uptake
• CTA (e-CTA) — LVO detection, automated collateral score (CTA-CS), multi-phase CTA support
• CTP (e-CTP) — perfusion summary maps, mismatch estimation, DAWN & DEFUSE 3 criteria matching
• MRI (e-MRI) — DWI, DWI-FLAIR mismatch, and DSC perfusion analysis for late-window patients

Results are typically available within 1–2 minutes of a scan being sent to the platform, delivered automatically via PACS, email notification, the Brainomix 360 mobile app, or web browser.

Brainomix 360 Stroke supports all major scanner and PACS manufacturers using the standard DICOM protocol. Brainomix engineers test all connections before go-live.

ASPECTS (Alberta Stroke Programme Early CT Score) is a 10-point scale used to quantify earlyischemic changes on non-contrast CT. A lower ASPECTS score indicates more brain damage. Brainomix's e-ASPECTS automates this score with a patented voxel-wise heatmap, delivering expert-level results in under 2 minutes — validated as non-inferior to expert scorers in a multicenter study.

Net Water Uptake is a first-of-its-kind, patented biomarker that provides a standardized percentage-based measure of ischemic tissue swelling, derived from NCCT scans. It helps inform treatment decisions and predict clinical outcomes.

Yes. Clinicians can review and edit automated ASPECTS and CTA collateral scores Manually adjusted results are clearly labelled and published to all result formats.

Yes. Pseudonymized email notifications are accessible from any device with hospital emailaccess. Full results are available remotely via any existing VPN or Citrix solution, and through the Brainomix 360 mobile app (iOS and Android).

The largest ever real-world evaluation of stroke AI — 452,000 patients, 107 hospitals, 5 years —published in The Lancet Digital Health (2025) showed that Brainomix 360 Stroke was associated with a 100% relative increase in mechanical thrombectomy rates.

Brainomix 360 e-Lung is an FDA-cleared, AI-powered imaging platform that automatically identifies and quantifies features on CT lung scans. It is designed to support earlier, more confident decisions in Interstitial Lung Disease (ILD) and Progressive Pulmonary Fibrosis (PPF)— conditions where early treatment initiation is critical to outcomes.

e-Lung is valuable at three key points in the patient journey:
‍
• At baseline diagnosis — to objectively quantify disease extent and establish a reference
• During serial monitoring — to detect progression, including subtle changes that may precede functional decline
• For MDT discussions — to guide treatment decisions and stratify patients by risk

• RVS (Reticular Vascular Structures) — fibrotic reticulation and vasculature
• WRVS (Weighted RVS) — RVS in the outer 10mm of lung (periphery); highly prognostic
• GGO (Ground Glass Opacity) — may reflect fibrosis or active inflammation
• TDE (Total Disease Extent) — the combined sum of RVS and GGO

High-resolution CT (HRCT), ≤2.5mm slice thickness, non-contrast preferred, with a sharper reconstruction kernel. Low-dose CT can be used as long as it is applied consistently acrossserial scans — avoid comparing HRCT with low-dose CT.

Yes. e-Lung can compare scans at each time point and normalize changes to annual rates, enabling reliable longitudinal monitoring. Imaging with e-Lung often detects progression before changes appear on pulmonary function tests (PFTs), so using both in combination gives the most complete picture.

REVISE PPF — a retrospective study conducted with the University of Chicago, Weill CornellMedical, and the University of Alabama at Birmingham — showed that:

• They could have supported an earlier PPF diagnosis in 71% of patients, and up to 28months earlier
• They identified CT progression in 74% of patients deemed clinically stable
• e-Lung metrics from a single baseline scan are independent predictors of mortality

Research has shown that e-Lung outperforms both FVC and visual radiologist assessment inprognostic accuracy and consistency — particularly in detecting subtle disease progression that may not yet be visible to the naked eye or measurable by lung function alone.

Yes. e-Lung is fully FDA-cleared for clinical use in the United States and has been validated inpartnership with Boehringer Ingelheim through the landmark INBUILD clinical trial dataset.

Vantage is the enterprise analytics dashboard that turns your AI imaging results into real-time, actionable insights across your entire stroke network. It provides a 360° view of clinical outcomes, clinician engagement, imaging throughput, and operational efficiency — across all sites, in one intuitive interface.

• Clinical outcomes — LVO detections, ASPECTS distribution, pathway tracking from triage to intervention
• Adoption & engagement — clinician app usage, time to first view, interventions over time
• Operational efficiency — processing speeds, CTA quality assurance, clinical workflow timings (door-to-door, groin puncture)
• Site benchmarking — compare performance across your network

Brainomix 360 is provided as a managed appliance on virtualized (cloud) or physical hardware. Brainomix engineers handle installation, scanner/PACS connections, protocol setup, and go-live testing in partnership with your hospital IT team.

All clinical users receive a group training presentation covering how to interpret results for each licensed module. User manuals are available in multiple languages at www.brainomix.com/user-manuals. Please see URL to request access (only available for current customers).

Contact the Brainomix support team:
‍
• Email: support@brainomix.com
• Support portal: www.brainomix.com/support
• UK office: +44 (0) 1865 582 730
• EU office: +353 1 636 3150

Patient data is stored on the Brainomix server inside the hospital and is not transmittedexternally. Email notifications contain pseudonymized results only. Brainomix is ISO 27001certified and GDPR compliant. A Data Processing Agreement (DPA) is available on request.